Ramshaw I A, Andrew M E, Phillips S M, Boyle D B, Coupar B E
Department of Experimental Pathology, John Curtin School of Medical Research, Australian National University, Canberra.
Nature. 1987;329(6139):545-6. doi: 10.1038/329545a0.
Vaccinia virus recombinants that express cloned genes encoding antigens of unrelated infectious agents, such as hepatitis B virus and human immunodeficiency virus (HIV), provide a new approach to the development of live vaccines. Although there is evidence that genetically engineered vaccinia viruses have reduced pathogenicity a major obstacle to their use as vaccines is that severe complications can occur after vaccination, especially in immunodeficient individuals. We describe here a recombinant vaccinia virus expressing murine interleukin-2 (IL-2) and show that athymic nude mice infected with the recombinant virus resolve the virus infection rapidly whereas mice infected with control virus develop a progressive vaccinal disease. By incorporating the gene for IL-2 in live virus vaccines it may be possible to prevent the severe complications that arise in recipients with an impaired immune system.
表达克隆基因（这些基因编码诸如乙肝病毒和人类免疫缺陷病毒（HIV）等不相关感染因子的抗原）的痘苗病毒重组体，为开发活疫苗提供了一种新方法。尽管有证据表明基因工程痘苗病毒的致病性已降低，但将其用作疫苗的一个主要障碍是接种疫苗后可能会出现严重并发症，尤其是在免疫缺陷个体中。我们在此描述一种表达小鼠白细胞介素-2（IL-2）的重组痘苗病毒，并表明感染重组病毒的无胸腺裸鼠能迅速消除病毒感染，而感染对照病毒的小鼠则会发展为进行性疫苗接种疾病。通过将IL-2基因纳入活病毒疫苗中，有可能预防免疫系统受损的接受者出现严重并发症。
